Ioflupan (123i) Rotop

Ioflupane, the active ingredient in Ioflupan (123i) Rotop, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used to evaluate Parkinsonian syndromes and other movement disorders by visualizing dopaminergic neuronal integrity. GNH USA supplies Ioflupan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and imaging centres worldwide.

Ioflupan (123i) Rotop is employed in diagnostic imaging of the dopaminergic system. - Parkinsonian syndromes: assists in confirming diagnosis by visualizing presynaptic dopamine transporter loss. - Differential diagnosis of movement disorders: helps distinguish Parkinson's disease from atypical parkinsonism. - Assessment of dopaminergic neuron loss: provides quantitative data on neuronal integrity for research and clinical monitoring.

Ioflupan (123i) Rotop may be associated with adverse reactions related to the radiopharmaceutical and its administration.

Common Side Effects: - Nausea: mild to moderate nausea reported after injection. - Headache: transient headache occurring shortly after administration. - Injection site discomfort: mild pain or irritation at the intravenous site. - Dizziness: temporary sensation of light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: anaphylaxis or severe hypersensitivity requiring immediate medical attention. - Radiation‑induced thyroid dysfunction: altered thyroid hormone levels due to iodine exposure. - Severe hypotension: marked drop in blood pressure following injection. - Pulmonary embolism: rare occurrence of embolic events related to the radiotracer.

Before using Ioflupan (123i) Rotop, consider the following precautions to ensure patient safety and product integrity. - Pregnancy: avoid use unless clearly needed, as fetal exposure to radiation is unknown. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration due to possible radiotracer excretion. - Renal impairment: assess kidney function, as reduced clearance may increase radiation dose. - Thyroid blocking: consider administering potassium iodide to reduce thyroid uptake of free iodine. - Contraindications: do not administer to patients with known hypersensitivity to iodine‑123 or any component of the formulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupan (123i) Rotop can interact with certain substances that affect iodine metabolism or imaging results.

Major Interactions (Avoid): - Thyroid hormone therapy: may interfere with tracer distribution and increase thyroid radiation dose. - Iodine‑containing contrast agents: can compete for uptake and reduce image quality; avoid within 24 hours of the scan.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of the radiotracer, requiring adjustment of imaging protocol. - Antihistamines: can mask mild allergic reactions, necessitating careful monitoring. - Other radiopharmaceuticals: concurrent administration may lead to cumulative radiation exposure; schedule appropriately.